Insight Molecular Diagnostics Stock Performance
| IMDX Stock | 5.82 0.41 7.58% |
Insight Molecular holds a performance score of 14 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 2.74, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Insight Molecular will likely underperform. Use Insight Molecular Diagnostics value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Insight Molecular Diagnostics.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Insight Molecular Diagnostics are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady fundamental indicators, Insight Molecular showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 7.58 | Five Day Return 12.36 | Year To Date Return 149.79 | Ten Year Return (96.40) | All Time Return (96.40) |
Last Split Factor 1:20 | Last Split Date 2023-07-25 |
1 | iMDx Reports Kidney Transplant Patient Achieved Immune Reset with Novel Therapy and GraftAssure Monitoring | 10/06/2025 |
2 | Acquisition by Arno Andrew of 141084 shares of Insight Molecular at 0.3544 subject to Rule 16b-3 | 10/28/2025 |
3 | Acquisition by Andrea James of 50000 shares of Insight Molecular subject to Rule 16b-3 | 10/31/2025 |
4 | Biodesix Gets a Buy from Lake Street - The Globe and Mail | 11/05/2025 |
5 | Insight Molecular Diagnostics Inc Q3 2025 Earnings Call Highlights Pioneering Advances ... | 11/12/2025 |
6 | Disposition of 12175 shares by Andrea James of Insight Molecular at 6.01 subject to Rule 16b-3 | 11/13/2025 |
7 | Will Insight Molecular Diagnostics Inc. stock remain on Wall Street radar - Analyst Upgrade Safe Investment Capital Preservation Plans - newser.com | 11/17/2025 |
8 | Acquisition by Riggs Josh of 800000 shares of Insight Molecular at 0.2132 subject to Rule 16b-3 | 11/20/2025 |
9 | Were Keeping An Eye On Insight Molecular Diagnostics Cash Burn Rate | 12/01/2025 |
10 | Hedge funds investors control 50 percent of Insight Molecular Diagnostics Inc. and were rewarded last week after stock increased 11 | 12/23/2025 |
| Begin Period Cash Flow | 11.1 M | |
| Total Cashflows From Investing Activities | -512 K |
Insight Molecular Relative Risk vs. Return Landscape
If you would invest 333.00 in Insight Molecular Diagnostics on September 26, 2025 and sell it today you would earn a total of 249.00 from holding Insight Molecular Diagnostics or generate 74.77% return on investment over 90 days. Insight Molecular Diagnostics is currently generating 1.0373% in daily expected returns and assumes 5.5443% risk (volatility on return distribution) over the 90 days horizon. In different words, 49% of stocks are less volatile than Insight, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Insight Molecular Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Insight Molecular's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Insight Molecular Diagnostics, and traders can use it to determine the average amount a Insight Molecular's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1871
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IMDX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Insight Molecular is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Insight Molecular by adding it to a well-diversified portfolio.
Insight Molecular Fundamentals Growth
Insight Stock prices reflect investors' perceptions of the future prospects and financial health of Insight Molecular, and Insight Molecular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Insight Stock performance.
| Return On Equity | -4.29 | ||||
| Return On Asset | -0.22 | ||||
| Operating Margin | (2.73) % | ||||
| Current Valuation | 54.24 M | ||||
| Shares Outstanding | 28.6 M | ||||
| Price To Book | 8.00 X | ||||
| Price To Sales | 22.55 X | ||||
| Revenue | 1.88 M | ||||
| Gross Profit | 2.09 M | ||||
| EBITDA | (59.02 M) | ||||
| Net Income | (60.66 M) | ||||
| Total Debt | 3.66 M | ||||
| Book Value Per Share | 0.36 X | ||||
| Cash Flow From Operations | (20.71 M) | ||||
| Earnings Per Share | (3.79) X | ||||
| Market Capitalization | 86.66 M | ||||
| Total Asset | 35.08 M | ||||
| Retained Earnings | (350.54 M) | ||||
| Working Capital | 4.48 M | ||||
About Insight Molecular Performance
Evaluating Insight Molecular's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Insight Molecular has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Insight Molecular has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 118.04 | 112.14 | |
| Return On Tangible Assets | (2.96) | (2.81) | |
| Return On Capital Employed | (2.20) | (2.09) | |
| Return On Assets | (1.73) | (1.82) | |
| Return On Equity | 4.94 | 5.19 |
Things to note about Insight Molecular performance evaluation
Checking the ongoing alerts about Insight Molecular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Insight Molecular help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Insight Molecular is way too risky over 90 days horizon | |
| Insight Molecular appears to be risky and price may revert if volatility continues | |
| Insight Molecular has high likelihood to experience some financial distress in the next 2 years | |
| Insight Molecular Diagnostics was previously known as OCX Old and was traded on NASDAQ Exchange under the symbol OCX. | |
| The company reported the previous year's revenue of 1.88 M. Net Loss for the year was (60.66 M) with profit before overhead, payroll, taxes, and interest of 2.09 M. | |
| Insight Molecular generates negative cash flow from operations | |
| About 56.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Hedge funds investors control 50 percent of Insight Molecular Diagnostics Inc. and were rewarded last week after stock increased 11 |
- Analyzing Insight Molecular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Insight Molecular's stock is overvalued or undervalued compared to its peers.
- Examining Insight Molecular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Insight Molecular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Insight Molecular's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Insight Molecular's stock. These opinions can provide insight into Insight Molecular's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Insight Stock Analysis
When running Insight Molecular's price analysis, check to measure Insight Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insight Molecular is operating at the current time. Most of Insight Molecular's value examination focuses on studying past and present price action to predict the probability of Insight Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insight Molecular's price. Additionally, you may evaluate how the addition of Insight Molecular to your portfolios can decrease your overall portfolio volatility.